Flow-Controlled vs. Pressure-Controlled Ventilation in CABG: Effects on Lung Aeration and Diaphragm Function (FCV-PCV-DTI-LU)
Comparison of Flow-Controlled Ventilation and Pressure-Controlled Ventilation on Lung Aeration and Diaphragm Function in Patients Undergoing Elective Isolated On-Pump Coronary Artery Bypass Graft Surgery: A Single-Centre Prospective Randomised Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ebru GIRGIN DINC, M.D., DESAIC
- Phone Number: 905446948852
- Email: grgnebru@gmail.com
Study Locations
-
-
Kartal
-
Istanbul, Kartal, Turkey (Türkiye), 34862
- Kosuyolu Heart Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years
- Planned elective isolated on-pump coronary artery bypass graft (CABG) surgery
- ASA Physical Status Classification II-IV
- Written informed consent obtained
- Technically adequate acoustic window for lung and diaphragm ultrasonography
Exclusion Criteria:
- Emergency surgery
- Combined surgical procedures (e.g., valve repair/replacement + CABG)
- Preoperative requirement for invasive or non-invasive mechanical ventilation
- Known diaphragm paralysis or neuromuscular disease
- Severe COPD exacerbation or active pneumonia at time of surgery
- Body mass index ≥40 kg/m²
- Inability to obtain standard lung or diaphragm ultrasound images due to pleural effusion, thoracic deformity, or prior thoracic surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: FCV (Flow-Controlled Ventilation)
Intraoperative ventilation with a Flow-Controlled Ventilation device.
Target tidal volume: 6-8 mL/kg ideal body weight (IBW).
PEEP and peak airway pressure titrated to maximise dynamic compliance.
Respiratory rate adjusted to maintain EtCO₂ 35-45 mmHg.
FiO₂ targeted to SpO₂ ≥94%.
|
PCV is delivered using a standard anaesthesia workstation in pressure-controlled mode.
Inspiratory pressure is set to achieve a tidal volume of 6-8 mL/kg ideal body weight.
PEEP is titrated using the same compliance-guided algorithm applied in the FCV arm.
Unlike FCV, the inspiratory flow profile is decelerating and PEEP and peak airway pressure are not independently optimised in a compliance-guided manner within the same ventilation mode
|
|
Active Comparator: PCV (Pressure-Controlled Ventilation)
Intraoperative pressure-controlled ventilation.
Inspiratory pressure adjusted to deliver a tidal volume of 6-8 mL/kg IBW.
PEEP titrated to maximise dynamic compliance, using the same algorithm as the FCV group.
Respiratory rate adjusted to maintain EtCO₂ 35-45 mmHg.
FiO₂ targeted to SpO₂ ≥94%.
|
FCV delivers tidal ventilation via a continuous triangular flow waveform, maintaining constant inspiratory and expiratory flow rates throughout the entire respiratory cycle.
PEEP and peak airway pressure are titrated independently, guided by dynamic respiratory system compliance.
Tidal volume target is 6-8 mL/kg ideal body weight.
This ventilation modality is distinct from pressure-controlled and volume-controlled modes, which generate decelerating inspiratory flow profiles and do not allow simultaneous independent titration of PEEP and peak airway pressure based on compliance.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Lung Ultrasound Score (LUS)
Time Frame: Preoperatively (T0), within 30 minutes of sternal closure while intubated (T1), and 24 hours postoperatively after extubation (T2)
|
Lung aeration assessed using a 12-zone bilateral ultrasonography protocol.
Each zone scored 0-3 (0 = normal aeration with A-lines; 1 = multiple B-lines; 2 = coalescent B-lines; 3 = consolidation).
Total score ranges from 0 to 36; higher scores indicate greater aeration loss
|
Preoperatively (T0), within 30 minutes of sternal closure while intubated (T1), and 24 hours postoperatively after extubation (T2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diaphragm Thickening Fraction (TFdi)
Time Frame: Preoperatively (T0), within 30 minutes of sternal closure while intubated (T1), and 24 hours postoperatively after extubation (T2)
|
Bilateral diaphragm thickening fraction measured via B-mode and M-mode ultrasonography at the zone of apposition using a linear probe (7-12 MHz).
TFdi (%) = [(T_insp - T_exp) / T_exp] × 100.
|
Preoperatively (T0), within 30 minutes of sternal closure while intubated (T1), and 24 hours postoperatively after extubation (T2)
|
|
Diaphragm Excursion
Time Frame: Preoperatively (T0), within 30 minutes of sternal closure while intubated (T1), and 24 hours postoperatively after extubation (T2)
|
Bilateral inspiratory diaphragm dome displacement measured via M-mode ultrasonography using a convex probe (2-5 MHz) via subcostal approach.
|
Preoperatively (T0), within 30 minutes of sternal closure while intubated (T1), and 24 hours postoperatively after extubation (T2)
|
|
PaO₂/FiO₂ Ratio
Time Frame: Preoperatively (T0), within 30 minutes of sternal closure while intubated (T1), and 24 hours postoperatively after extubation (T2)
|
Ratio of arterial oxygen partial pressure to fractional inspired oxygen, calculated from arterial blood gas analysis.
|
Preoperatively (T0), within 30 minutes of sternal closure while intubated (T1), and 24 hours postoperatively after extubation (T2)
|
|
Postoperative Pulmonary Complications
Time Frame: Up to 30 days postoperatively
|
Composite of clinically significant pulmonary complications including radiologically confirmed atelectasis, pneumonia, and re-intubation, assessed according to pre-specified definitions.
|
Up to 30 days postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ebru GIRGIN DINC, Koşuyolu Kartal Heart Training and Research Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FCV-PCV-DTI-LUS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.